Brian Topp

1.2k total citations
21 papers, 874 citations indexed

About

Brian Topp is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Brian Topp has authored 21 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Brian Topp's work include Cancer Immunotherapy and Biomarkers (10 papers), Pancreatic function and diabetes (6 papers) and Diabetes and associated disorders (4 papers). Brian Topp is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Pancreatic function and diabetes (6 papers) and Diabetes and associated disorders (4 papers). Brian Topp collaborates with scholars based in United States, Canada and United Kingdom. Brian Topp's co-authors include Diane T. Finegood, M. Dawn McArthur, Robin E. Buckingham, Thomas B. Leonard, Robert M. Miura, Keith Promislow, Laura L. Atkinson, Alexandra Snyder, Mark Penney and Alice Tsai and has published in prestigious journals such as Cancer Cell, Cancer Research and Diabetes.

In The Last Decade

Brian Topp

20 papers receiving 833 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Topp United States 11 407 380 362 212 125 21 874
Marisa W. Medina United States 22 502 1.2× 129 0.3× 560 1.5× 314 1.5× 74 0.6× 47 1.4k
Eliana Polisecki United States 17 473 1.2× 229 0.6× 163 0.5× 97 0.5× 61 0.5× 32 829
Kumi Satoh Japan 17 331 0.8× 136 0.4× 297 0.8× 57 0.3× 103 0.8× 63 880
Marlena Maziarz United States 15 316 0.8× 319 0.8× 315 0.9× 184 0.9× 89 0.7× 41 869
Dragi Anevski Sweden 9 367 0.9× 332 0.9× 328 0.9× 447 2.1× 102 0.8× 21 1.1k
Hongwen Zhou China 18 378 0.9× 210 0.6× 660 1.8× 48 0.2× 228 1.8× 61 1.2k
Marisa Viñals Spain 10 398 1.0× 175 0.5× 332 0.9× 48 0.2× 161 1.3× 13 873
Parag Garhyan United States 15 369 0.9× 499 1.3× 363 1.0× 79 0.4× 106 0.8× 34 854
William M. Sallas United States 10 177 0.4× 309 0.8× 194 0.5× 33 0.2× 56 0.4× 19 758
Weixiong Lin China 16 174 0.4× 163 0.4× 199 0.5× 124 0.6× 68 0.5× 55 756

Countries citing papers authored by Brian Topp

Since Specialization
Citations

This map shows the geographic impact of Brian Topp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Topp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Topp more than expected).

Fields of papers citing papers by Brian Topp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Topp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Topp. The network helps show where Brian Topp may publish in the future.

Co-authorship network of co-authors of Brian Topp

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Topp. A scholar is included among the top collaborators of Brian Topp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Topp. Brian Topp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monette, Anne, Sarah H. Warren, J. Carl Barrett, et al.. (2024). Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee. Journal for ImmunoTherapy of Cancer. 12(7). e009427–e009427. 8 indexed citations
2.
Mohan, Aparna, et al.. (2024). A bootstrapping method to optimize go/no‐go decisions from single‐arm, signal‐finding studies in oncology. CPT Pharmacometrics & Systems Pharmacology. 13(8). 1317–1326. 3 indexed citations
3.
Kumar, Rukmini, et al.. (2023). Incorporating lesion-to-lesion heterogeneity into early oncology decision making. Frontiers in Immunology. 14. 1173546–1173546. 5 indexed citations
4.
Topp, Brian, Alexandra Snyder, & Jedd D. Wolchok. (2023). RECISTv1.1 progression in oncology: Shades of gray. Cancer Cell. 41(6). 1003–1005. 7 indexed citations
5.
Topp, Brian, Kapil Mayawala, Dinesh P. de Alwis, et al.. (2023). Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell. 41(9). 1680–1688.e2. 19 indexed citations
6.
Armand, Philippe, Pier Luigi Zinzani, John M. Timmerman, et al.. (2023). FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB. Hematological Oncology. 41(S2). 163–165. 1 indexed citations
7.
Zalba, Sara, Marı́a J. Garrido, Pedro Berraondo, et al.. (2021). Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. Cancers. 13(20). 5049–5049. 3 indexed citations
8.
Topp, Brian, et al.. (2021). Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab. Annals of Oncology. 32(12). 1618–1625. 19 indexed citations
9.
Kumar, Rukmini, Lakshmanan Jagannathan, Li Liu, et al.. (2021). Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response. CPT Pharmacometrics & Systems Pharmacology. 10(7). 684–695. 13 indexed citations
10.
Zalba, Sara, Virginia Belsúe, Brian Topp, et al.. (2021). Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1. British Journal of Cancer. 124(7). 1275–1285. 6 indexed citations
11.
Topp, Brian, et al.. (2020). Abstract PO-131: Inter-tumoral heterogeneity of progressive disease in melanoma patients treated with pembrolizumab. Cancer Research. 80(21_Supplement). PO–131. 1 indexed citations
12.
Spilker, Mary E., Richard Zang, Handan He, et al.. (2019). Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities. CPT Pharmacometrics & Systems Pharmacology. 8(11). 777–791. 60 indexed citations
13.
Nijsen, Marjoleen, Erica L. Bradshaw‐Pierce, Jason R. Chan, et al.. (2018). Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. CPT Pharmacometrics & Systems Pharmacology. 7(3). 135–146. 64 indexed citations
14.
Waters, Steven B., Brian Topp, Scott Q. Siler, & Charles M. Alexander. (2009). Treatment with Sitagliptin or Metformin Does Not Increase Body Weight despite Predicted Reductions in Urinary Glucose Excretion. Journal of Diabetes Science and Technology. 3(1). 68–82. 14 indexed citations
15.
Atkinson, Laura L., et al.. (2009). Quantification of the relationship between glycemia and β-cell mass adaptation in vivo. Canadian Journal of Physiology and Pharmacology. 87(8). 602–609. 1 indexed citations
16.
Topp, Brian, Laura L. Atkinson, & Diane T. Finegood. (2007). Dynamics of insulin sensitivity, β-cell function, and β-cell mass during the development of diabetes in fa/fa rats. American Journal of Physiology-Endocrinology and Metabolism. 293(6). E1730–E1735. 47 indexed citations
17.
Topp, Brian, M. Dawn McArthur, & Diane T. Finegood. (2004). Metabolic adaptations to chronic glucose infusion in rats. Diabetologia. 47(9). 1602–1610. 55 indexed citations
18.
Finegood, Diane T., et al.. (2001). β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats. Diabetes. 50(5). 1021–1029. 312 indexed citations
19.
Finegood, Diane T. & Brian Topp. (2001). β‐cell deterioration – prospects for reversal or prevention. Diabetes Obesity and Metabolism. 3(s1). 20–27. 20 indexed citations
20.
Topp, Brian, et al.. (2000). A Model of β -Cell Mass, Insulin, and Glucose Kinetics: Pathways to Diabetes. Journal of Theoretical Biology. 206(4). 605–619. 214 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marisa W. Medina Breakdown of academic impact, for papers by Eliana Polisecki Breakdown of academic impact, for papers by Kumi Satoh Breakdown of academic impact, for papers by Marlena Maziarz Breakdown of academic impact, for papers by Dragi Anevski Breakdown of academic impact, for papers by Hongwen Zhou Breakdown of academic impact, for papers by Marisa Viñals Breakdown of academic impact, for papers by Parag Garhyan Breakdown of academic impact, for papers by William M. Sallas Breakdown of academic impact, for papers by Weixiong Lin
Rankless by CCL
2026